Legal & General Group
CTNM

Legal & General Group’s Contineum Therapeutics CTNM Stock Holding History

Legal & General Group’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$42.8K Buy
+2,614
New +$34.3K ﹤0.01% 2820
2025
Q2 		– Sell
-3,631
Closed -$25.3K – 3571
2025
Q1 		$25.3K Hold
3,631
– – ﹤0.01% 2861
2024
Q4 		$53.2K Buy
3,631
+1,544
+74% +$24.4K ﹤0.01% 2769
2024
Q3 		$39.9K Hold
2,087
– – ﹤0.01% 2829
2024
Q2 		$36.6K Buy
+2,087
New +$33.6K ﹤0.01% 2837

Other funds holding CTNM

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Legal & General Group's CTNM Position: Q2 2026 in Review

Legal & General Group opened a new position in Contineum Therapeutics (CTNM) in Q2 2026: 2,614 shares worth $42.8K. The stake represents ﹤0.01% of the portfolio and ranks #2820 among its holdings. This is a return to the name: Legal & General Group previously reported a position in CTNM as recently as Q1 2025.

Legal & General Group first reported a position in CTNM in Q2 2024 and has held it in 5 quarters since. The position peaked at $53.2K in Q4 2024. 102 funds tracked by Wall St. Rank hold CTNM as of Q2 2026.

  • Legal & General Group held 2,614 shares of Contineum Therapeutics worth $42.8K as of Q2 2026.
  • Contineum Therapeutics was a new Legal & General Group position in Q2 2026.
  • Contineum Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #2820 holding.
  • Legal & General Group first reported a position in Contineum Therapeutics in Q2 2024 and has held it in 5 quarters since.
  • Legal & General Group's Contineum Therapeutics position peaked at $53.2K in Q4 2024.
  • 102 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.